Diurnal Limited, Cardiff, UK is pleased to announce that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Institute of Health (NIH), Maryland, US. The title of the CRADA is "Age-Appropriate Hydrocortisone Formulations for the Treatment of Adrenal Insufficiency including Congenital Adrenal Hyperplasia" and the research aims to investigate the use of Chronocort® (circadian hydrocortisone) in patients who suffer from these rare (orphan) diseases.
Martin Whitaker, General Manager, Diurnal, stated:
"We are delighted that Diurnal has entered into this CRADA agreement with the National Institute of Health and we look forward to working with the NIH clinical team to further progress our knowledge of treating Adrenal Insufficiency and Congenital Adrenal Hyperplasia"
For further information please contact:
Martin Whitaker, PhD (General Manager)
+44 (0) 871 716 8848